Industry, academia and publicly funded research agencies are invited to participate in an audit of Australia’s capability and capacity to support Medical Countermeasures (MCM) product research and development.

The audit is being carried out by the Defence Science and Technology (DST) Group in collaboration with d3 Medicine, a Certara Company. An initial audit in 2012 showed Australia is home to a small, but internationally networked medical technology, biotechnology and pharmaceutical sector with pockets of MCM development excellence.

The results of 2012 audit leveraged $7 million in funding to support a number of collaborative projects and provided evidence for MCM products to be included in the NGTF.

This 2017 audit now seeks to understand how the medical technology, biotechnology and pharmaceutical sector has changed since 2012. It will determine where MCM assets, capabilities and capacities lie, helping to shape an MCM Business Plan under the NGTF.

This information will be collected via an online survey that takes between 15-45 minutes.

To access the survey, please head to MCM Survey.

The National Capability Audit closes on Monday 10 April 2017.